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tions: three patients complained of severe asthenia, two suf-
fered gastrointestinal intolerance and two anxiety. All these
adverse events, except anxiety, were similar to those reported
in previous studies. Symptoms disappeared when ABC was
stopped. Some authors have claimed that ABC does not need
to be removed if rash is the only manifestation [10]. However,
minor symptoms associated with rash are quite common and
doctors should be concerned about the potential of a more
severe reaction, and allow ABC to be withdrawn more fre-
quently.
In conclusion, in a clinical setting ABC was relatively safe.
Overall, 4% of subjects developed hypersensitivity, which
always resolved when the drug was discontinued. However,
the total rate of discontinuation was 8%, which is slightly
higher than that reported in original clinical trials.
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Gram-positive anaerobic cocci (GPAC) account for one-
fourth to one-third of all anaerobic isolates recovered from
clinical specimens, and Gram-negative anaerobic cocci
(GNAC), predominantly the veillonellae, constitute up to
6.3% [1^3]. Anaerobic cocci have often been encountered in
head and neck, lung, intestinal, gynecologic and soft-tissue
infections [4,5]. These organisms have been considered as a`n
important but neglected group'; reasons include di¤culties
with laboratory isolation, their frequent involvement in poly-
microbial infections, and anticipated susceptibility to most
antimicrobial agents used to treat anaerobic infections [2].
However, recent studies have reported an increase in resistance
of anaerobic cocci to b-lactams, lincosamides and nitroimida-
zoles [6^8].
The aims of this study were: to evaluate the commonest
species of anaerobic cocci isolated in the university hospital of
pulmonary diseases and several other university hospitals in
So¢a, to determine the resistance patterns to four antimicro-
bial agents, considered as drugs of choice for treating anaero-
bic infections, and to assess the resistance to more than one
agent among the isolates.
FromOctober1996 toMay1999, 42 consecutive non-dupli-
cate clinical isolates of anaerobic cocci from 41 adult patients
were evaluated, comprising Peptostreptococcus anaerobius (seven
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isolates), P.micros (eight), P.magnus (11), the P. prevotii/P. tetradius
group (six), P. asaccharolyticus (two), unidenti¢ed Peptostrepto-
coccus species (three), andVeillonella species (¢ve). Most isolates
(30/42) were from pleuropulmonary infections. Specimens
were cultured on Schaedler agar (Becton Dickinson, Heidel-
berg, Germany) enriched with 5% sheep blood, vitamin K,
hemin and sodium pyruvate [9], andwere incubated anaerobi-
cally using Anaerogen (Oxoid, Basingstoke, UK) or Gas Pak
anaerobic system envelopes (Becton Dickinson) at 37 C for
2^7 days. Isolates were identi¢ed by the Crystal anaerobes
identi¢cation system (BBL, Cockeysville, MD, USA) and
routinemethods [1,9,10].
Susceptibility testing of 39 isolates was performed, 16 of
them being tested by the broth microdilution method
(BMDM) Sceptor MIC system for anaerobic bacteria (BBL
Microbiology Systems, Cockeysville, MD, USA) by follow-
ing the manufacturer's guidelines. Minimal inhibitory con-
centrations (MICs) were read after 48 h of anaerobic
incubation at 37 C [9,11].
The limited agar dilution method (LADM) [11,12] was
used for susceptibility testing of all 39 isolates.The activities of
penicillin 0.5 and 1mg/L were tested against 21 isolates. The
following drugs were tested: cefoxitin (Sigma Chemical Co.,
St Louis, Mo, USA); metronidazole (Sigma Chemical Co. or
Troya Pharm,Troyan, Bulgaria); and penicillin and clindamy-
cin (Antibiotic Co., Razgrad, Bulgaria).This method was car-
ried out using enriched Schaedler blood agar plates containing
several concentrations of each antimicrobial agent as follows:
penicillin (0.5, 1, 2 and 4mg/L), cefoxitin (16 and 32mg/L),
clindamycin (2 and 4mg/L) and metronidazole (8 and 16mg/
L). Final inocula of approximately 5106 CFU/spot were
inoculated onto these media and the plates were incubated at
37 C for 48 h. The strains were divided into three categories
according to the NCCLS [11].The breakpoints indicating sus-
ceptibility were 0.5mg/L for penicillin, 2mg/L for clinda-
mycin, 16mg/L for cefoxitin, and 8mg/L for metronidazole.
Strains inhibited by penicillin 1mg/L, clindamycin 4mg/L,
cefoxitin 32mg/L and metronidazole 16mg/L were deemed
to be intermediate, and those showing higherMICs were con-
sidered to be resistant to the corresponding drug.The LADM
was performed in duplicate. Non-selective medium plates
were used as controls of strain viability.
P. magnus was the commonest species of anaerobic coccus
(26.2% of the 42 isolates), followed by P. micros (19%) and P.
anaerobius (16.7%). One-seventh (14.3%) of the isolates were
identi¢ed as belonging to the P. prevotii/P. tetradius group.
P. magnus is one of the commonest and most pathogenic
species of GPAC, accounting for 20^33% of all GPAC isolates
and elaborating virulence factors, e.g. collagenase, gelatinase
and capsule formation [1,13]. It is now established that P. mag-
nus, P. anaerobius and P. micros demonstrate synergy with facul-
tative and anaerobic bacteria. Ability to produce abscesses and
capsule formation are important virulence factors as well
[2,13].
Veillonella species accounted for 11.9% (5/42) of isolates.
Wren [1] has reported ¢ve (2.9%) Veillonella strains among 169
isolates of anaerobic cocci. However, Brook [3] has detected
GNAC in 6.3% of the specimens submitted for anaerobic cul-
ture.The present results show a relatively frequent recovery of
Veillonella species, probably because the origin of most speci-
menswas above the diaphragm.
The clinical importance of anaerobic cocci, their virulence
and emerging antimicrobial resistance increase the value of
susceptibility testing of isolates. However, the NCCLS refer-
ence agar dilution method is not convenient for routine test-
ing of individual strains [14]; the broth disk elution method is
no longer recommended by the NCCLS [11,14]; and the E-
test is rather expensive for everyday use inmany laboratories.
In the present study, BMDM was used for susceptibility
testing of 16 isolates.TheMIC50 andMIC90 values were as fol-
lows: 0.25 and 0.5mg/L for penicillin, 0.5 and 4mg/L for
cefoxitin, 1 and 8mg/L for clindamycin, 4 and>32mg/L for
erythromycin, and 2 and 64mg/L for metronidazole, respec-
tively. However, some strains, e.g. P. micros, did not grow in
the liquid medium. Dubreuil et al [14] have recently reported
that 18 of 25 Peptostreptococcus isolates did not grow well in
ATB S liquid medium. Thus, the LADM was carried out for
testing the strains, and the results used are from this method.
All the isolates were uniformly susceptible only to cefoxi-
tin, and most of them (85.7%,18/21) were susceptible to peni-
cillin 0.5mg/L. Penicillin resistance (MICs r2mg/L) was
found in 7.7% (3/39) of isolates, includingVeillonella spp. (two
isolates) and P. magnus (one isolate). For twoVeillonella spp. iso-
lates, the penicillin MICs were 4 and r8mg/L, respectively.
Penicillin resistance of Veillonella species has been previously
described by Reig et al, who reported that 80% of the strains
exhibited penicillin MICs of >2mg/L, and the penicillin
MIC50 and MIC90 values were 16 and 64mg/L, respectively
[15].
The penicillin-resistant P. magnus strain, together with P.
anaerobius and Prevotella bivia, was detected in peritoneal £uid
in a case of peritonitis.The prior therapy consisted of cefotax-
ime, amikacin and metronidazole; however, the strain
remained susceptible to cefoxitin and metronidazole. Peptos-
treptococcus resistance to penicillin ranging from 0% to 12%
has been reported [6,7,16].This resistance has been found in P.
magnus isolates as well, according toWren [1].
The susceptibility of Peptostreptococcus species to metronida-
zole is a matter of controversy. Many authors [1, 17, 18] main-
tain that almost all peptostreptococci are metronidazole
susceptible. Recently, metronidazole resistance has been found
in 6% of GPAC by Citron et al [19] and Koch et al [7], includ-
ing 10% of P. anaerobius isolates. Higher metronidazole resis-
tance in GPAC was observed in the present work. Of the 35
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Peptostreptococcus isolates tested, 5.7% were intermediate and
8.6%were resistant tometronidazole.The strains less suscepti-
ble to metronidazole belonged to P. magnus, the P. prevotii/P.
tetradius group and P. anaerobius. Metronidazole resistance in P.
magnus and P. anaerobius has been detected by other authors as
well [2,6], and a single study has reported resistance to metro-
nidazole by disk testing in the P. prevotii/P. tetradius group [2].
The fourVeillonella isolates were fully susceptible to metroni-
dazole and clindamycin.
The present results suggest that the susceptibility of GPAC
to metronidazole and clindamycin is unpredictable. Among
GPAC, 8.6% (3/35) were clindamycin resistant and belonged
to P. magnus, the P. prevotii/P. tetradius group and an unidenti-
¢ed Peptostreptococcus species. Four isolates (11.4%), including
P. magnus (three isolates) and P. anaerobius (one isolate), had
intermediate susceptibility to clindamycin. Increasing clinda-
mycin resistance in GPAC has recently been observed world-
wide and ranges from 0% to 28% [6,8,18^20].
Erythromycin MICs were >8mg/L for three (27.3%) of
the 11 clindamycin-susceptible GPAC isolates, tested by
BMDM, which could be considered as isolates with macro-
lide^lincosamide^streptogramin B-inducible resistance. As
inducible macrolide^lincosamide resistance in GPAC species
has been previously described, it is recommended to check
erythromycin susceptibility before isolates are reported as sus-
ceptible to clindamycin [21,22].
Two strains (5.1%) of all 39 isolates exhibited double resis-
tance or intermediate susceptibility to both clindamycin and
metronidazole. Both strains were identi¢ed as P. magnus.
Emergence of double resistance among GPAC could be of
utmost importance, since some therapeutic regimens may be
compromised.
In conclusion, most GPAC isolates did not grow well in
the broth microdilution system used. The susceptibility pat-
terns of anaerobic cocci to several drugs are unpredictable. P.
magnus was more resistant to antimicrobial agents than the
other GPAC tested; moreover, it was the commonest isolate in
the group. The emergence of double resistance among GPAC
may re£ect an alarming tendency.
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